It will also be important to test other proapoptotic agents, for example, Bcl-XL- or Mcl-1–specific inhibitors (49, 50) for their potency for killing adenomas in the presence of sulindac or PP, and whether those drugs might enhance the reduction of colon adenomas by the combined PP/sulindac treatment. The gene discussed is BCL2L1; the disease is colon adenoma.